Disseminated cryptococcosis

Disseminated cryptococcosis is a fungal disease entity recognized in the source material as the systemic counterpart to localized cutaneous cryptococcosis, with emphasis on whether lesions are disseminated rather than confined to the skin ^[1]. The available classification language treats it as cutaneous manifestations of disseminated cryptococcosis rather than purely route-based categories, reflecting a clinical distinction between localized and systemic disease ^[1]. Source-backed detail on the etiologic species, anatomic staging, or formal case definition is not yet available.

The source snippets do not provide a detailed symptom profile for disseminated cryptococcosis, but they indicate that the condition may manifest as cutaneous disease within a disseminated/systemic process ^[1]. In the COVID-19-associated case literature, cryptococcosis was described as potentially life-threatening, and severe illness was often reported in patients with multiple comorbidities ^[2]. The review also notes that many affected patients were managed in intensive care settings, although the disease-specific clinical course beyond this association is not fully described in the provided material ^[2]. Source-backed detail on organ involvement, complication pattern, or typical presenting signs is not yet available.

The provided evidence does not define a global or regional incidence pattern for disseminated cryptococcosis, but it does show that disseminated/systemic disease is a relevant clinical category in published cryptococcosis guidance ^[1]. In one scoping review of COVID-19-associated cryptococcosis, cases were infrequently reported but clinically significant, with 58 studies included and 65 patients described through individual patient data ^[2]. That review reported a predominance of male patients, a median age of 60 years, frequent severe COVID-19, and multiple comorbidities such as arterial hypertension and diabetes mellitus ^[2]. Another review of HIV-associated dermatologic disease lists disseminated cryptococcosis among opportunistic infections seen in HIV infection/AIDS ^[3].

The source material does not provide a definitive transmission route for disseminated cryptococcosis. One reviewed article notes that cutaneous cryptococcosis may be classified as primary or secondary based on route of infection, but it also stresses that the more important clinical distinction is localized versus disseminated/systemic disease ^[1]. Because the snippets do not specify the exposure mechanism for disseminated disease, source-backed detail on transmission is not yet available.

The source snippets identify immunocompromised patients as an important affected group in cryptococcal skin disease, and they also note disseminated cryptococcosis among opportunistic infections associated with HIV infection/AIDS ^[1][3]. In the COVID-19-associated review, many patients had severe COVID-19 and multiple comorbidities, with arterial hypertension and diabetes mellitus frequently reported ^[2]. The same review states that few patients had classic immunosuppression factors, indicating that disseminated cryptococcosis may also be observed outside traditional immunocompromised categories in this context ^[2].

The supplied sources do not give specific preventive measures for disseminated cryptococcosis. They do indicate that the disease is clinically important in immunocompromised patients and in the context of HIV infection/AIDS, as well as among patients with severe COVID-19 and multiple comorbidities ^[1][2][3]. Source-backed detail on prophylaxis, environmental control, or vaccine-related prevention is not yet available.

For surveillance purposes, the available literature suggests reading disseminated cryptococcosis as a systemic cryptococcal syndrome rather than as a purely localized cutaneous process ^[1]. It is particularly relevant when monitoring opportunistic infections in HIV/AIDS and severe COVID-19 populations, where reported cases may reflect clinically severe illness and substantial comorbidity burden ^[2][3]. Because the provided sources are limited, source-backed detail on standard case-finding thresholds, laboratory confirmation criteria, or reporting definitions is not yet available.

1. 1 Noguchi H et al. Cutaneous Cryptococcosis. Med Mycol J. 2019. PMID: 31787730. doi: 10.3314/mmj.19.008. PubMed: https://pubmed.ncbi.nlm.nih.gov/31787730/
2. 2 Quincho-Lopez A et al. COVID-19 associated with cryptococcosis: a scoping review. Ther Adv Infect Dis. 2024 Jan-Dec. PMID: 38361915. doi: 10.1177/20499361241232851. PubMed: https://pubmed.ncbi.nlm.nih.gov/38361915/
3. 3 Mohseni Afshar Z et al. A Comprehensive Review on HIV-Associated Dermatologic Manifestations: From Epidemiology to Clinical Management. Int J Microbiol. 2023. PMID: 37496761. doi: 10.1155/2023/6203193. PubMed: https://pubmed.ncbi.nlm.nih.gov/37496761/
4. 4 Disseminated cryptococcosis. Journal of Skin and Sexually Transmitted Diseases. 2019. doi: 10.25259/jsstd_23_2019. DOI: https://doi.org/10.25259/jsstd_23_2019
5. 5 Disseminated cryptococcosis. Indian Pediatrics. 2014. doi: 10.1007/s13312-014-0356-5. DOI: https://doi.org/10.1007/s13312-014-0356-5
6. 6 Disseminated cryptococcosis. Indian Journal of Dermatology, Venereology, and Leprology. 2016. doi: 10.4103/0378-6323.164216. DOI: https://doi.org/10.4103/0378-6323.164216

ICD-10

ICD-11

Total cases

1K

Peak month

2024-03

Coverage

1 reporting countries · 2014-09-19 → 2026-06-20